UniProt ID | TRI22_HUMAN | |
---|---|---|
UniProt AC | Q8IYM9 | |
Protein Name | E3 ubiquitin-protein ligase TRIM22 | |
Gene Name | TRIM22 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 498 | |
Subcellular Localization | Cytoplasm . Nucleus . Nucleus speckle. Nucleus, Cajal body. Localizes predominantly to the nucleus, found in cytoplasm to some extent. Forms distinct nuclear bodies that undergo dynamic changes during cell cycle progression. Nuclear bodies start to f | |
Protein Description | Interferon-induced antiviral protein involved in cell innate immunity. The antiviral activity could in part be mediated by TRIM22-dependent ubiquitination of viral proteins. Plays a role in restricting the replication of HIV-1, encephalomyocarditis virus (EMCV) and hepatitis B virus (HBV). Acts as a transcriptional repressor of HBV core promoter. May have E3 ubiquitin-protein ligase activity.. | |
Protein Sequence | MDFSVKVDIEKEVTCPICLELLTEPLSLDCGHSFCQACITAKIKESVIISRGESSCPVCQTRFQPGNLRPNRHLANIVERVKEVKMSPQEGQKRDVCEHHGKKLQIFCKEDGKVICWVCELSQEHQGHQTFRINEVVKECQEKLQVALQRLIKEDQEAEKLEDDIRQERTAWKNYIQIERQKILKGFNEMRVILDNEEQRELQKLEEGEVNVLDNLAAATDQLVQQRQDASTLISDLQRRLRGSSVEMLQDVIDVMKRSESWTLKKPKSVSKKLKSVFRVPDLSGMLQVLKELTDVQYYWVDVMLNPGSATSNVAISVDQRQVKTVRTCTFKNSNPCDFSAFGVFGCQYFSSGKYYWEVDVSGKIAWILGVHSKISSLNKRKSSGFAFDPSVNYSKVYSRYRPQYGYWVIGLQNTCEYNAFEDSSSSDPKVLTLFMAVPPCRIGVFLDYEAGIVSFFNVTNHGALIYKFSGCRFSRPAYPYFNPWNCLVPMTVCPPSS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
44 | Ubiquitination | ACITAKIKESVIISR HHHHHEECCCEEEEC | 43.14 | - | |
46 | Phosphorylation | ITAKIKESVIISRGE HHHEECCCEEEECCC | 17.39 | 23403867 | |
55 | Phosphorylation | IISRGESSCPVCQTR EEECCCCCCCCCCCC | 20.38 | - | |
87 | Phosphorylation | RVKEVKMSPQEGQKR HHHHHCCCCCCCCCC | 20.08 | 23401153 | |
173 (in isoform 1) | Ubiquitination | - | 37.09 | 21890473 | |
173 | Ubiquitination | RQERTAWKNYIQIER HHHHHHHHHHHHHHH | 37.09 | 21890473 | |
182 | Ubiquitination | YIQIERQKILKGFNE HHHHHHHHHHCCCCE | 57.11 | - | |
185 | Ubiquitination | IERQKILKGFNEMRV HHHHHHHCCCCEEEE | 66.00 | - | |
204 | Ubiquitination | EEQRELQKLEEGEVN HHHHHHHHHHCCCCC | 71.18 | - | |
261 | Phosphorylation | DVMKRSESWTLKKPK HHHHHCCCCCCCCCC | 26.97 | 28555341 | |
325 | Phosphorylation | VDQRQVKTVRTCTFK EEHHHEEEEEEEEEC | 19.16 | 22817900 | |
373 | Phosphorylation | AWILGVHSKISSLNK EEEEEHHHHHHHCCC | 29.31 | - | |
376 | Phosphorylation | LGVHSKISSLNKRKS EEHHHHHHHCCCCCC | 32.29 | 27794612 | |
377 | Phosphorylation | GVHSKISSLNKRKSS EHHHHHHHCCCCCCC | 39.16 | 23403867 | |
380 | Ubiquitination | SKISSLNKRKSSGFA HHHHHCCCCCCCCCC | 67.50 | - | |
382 | Ubiquitination | ISSLNKRKSSGFAFD HHHCCCCCCCCCCCC | 51.05 | - | |
383 | Phosphorylation | SSLNKRKSSGFAFDP HHCCCCCCCCCCCCC | 39.46 | 23401153 | |
384 | Phosphorylation | SLNKRKSSGFAFDPS HCCCCCCCCCCCCCC | 40.75 | 30266825 | |
391 | Phosphorylation | SGFAFDPSVNYSKVY CCCCCCCCCCHHHHH | 25.49 | 23403867 | |
392 (in isoform 2) | Ubiquitination | - | 10.69 | 21890473 | |
394 | Phosphorylation | AFDPSVNYSKVYSRY CCCCCCCHHHHHHCC | 14.02 | 23403867 | |
396 | Ubiquitination | DPSVNYSKVYSRYRP CCCCCHHHHHHCCCC | 34.53 | 21890473 | |
396 (in isoform 1) | Ubiquitination | - | 34.53 | 21890473 | |
405 | Phosphorylation | YSRYRPQYGYWVIGL HHCCCCCCCEEEEEE | 18.18 | 24043423 | |
407 | Phosphorylation | RYRPQYGYWVIGLQN CCCCCCCEEEEEEEC | 7.49 | 24043423 | |
415 | Phosphorylation | WVIGLQNTCEYNAFE EEEEEECEEEEECCC | 8.18 | 24043423 | |
418 | Phosphorylation | GLQNTCEYNAFEDSS EEECEEEEECCCCCC | 17.59 | 24043423 | |
424 | Phosphorylation | EYNAFEDSSSSDPKV EEECCCCCCCCCCCC | 25.56 | 24043423 | |
425 | Phosphorylation | YNAFEDSSSSDPKVL EECCCCCCCCCCCCE | 46.30 | 24043423 | |
426 | Phosphorylation | NAFEDSSSSDPKVLT ECCCCCCCCCCCCEE | 42.59 | 24043423 | |
427 | Phosphorylation | AFEDSSSSDPKVLTL CCCCCCCCCCCCEEE | 60.94 | 24043423 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of TRI22_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of TRI22_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
ZZZ3_HUMAN | ZZZ3 | physical | 20211142 | |
TRI22_HUMAN | TRIM22 | physical | 17156811 | |
TAB2_HUMAN | TAB2 | physical | 23818111 | |
IF4E_HUMAN | EIF4E | physical | 22509910 | |
IKKA_HUMAN | CHUK | physical | 25510414 | |
C2TA_HUMAN | CIITA | physical | 28555140 | |
PML_HUMAN | PML | physical | 28555140 | |
CCNT1_HUMAN | CCNT1 | physical | 28555140 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...